ImmunityBio said the QUILT 3.055 trial shows median overall survival almost double that of standard of care chemotherapy. The FDA approved the company’s Anktiva plus Bacillus Calmette-Guérin ...

FREMONT, Calif., Nov. 21, 2024 /PRNewswire/ -- ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated biotechnology company, and nCartes, Inc., a transformational ...

It has been roughly three months since my last ImmunityBio, Inc. (NASDAQ:IBRX) article, where I discussed the company's $100M public offering, which I thought was necessary to support the company ...

CULVER CITY, Calif., March 26, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be ...

ImmunityBio is a clinical-stage biotech company. The company's lead therapy candidate is Anktiva. The company has a pipeline with 13 programs. Shares of ImmunityBio (NASDAQ: IBRX) were up 10% at ...